NCT04456049View on ClinicalTrials.gov

Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-1

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

August 24, 2020

Primary Completion Date

June 9, 2021

Study Completion Date

June 9, 2021

Conditions
COVID-19 Infection
Interventions
DRUG

Enzalutamide

40 mg oral tablets once daily for a maximum of 28 days.

Trial Locations (1)

6500

Oncology Institute of Southern Switzerland (IOSI), Bellinzona

Sponsors
All Listed Sponsors
collaborator

Oncology Institute of Southern Switzerland

OTHER

collaborator

Institute of Oncology Research

UNKNOWN

collaborator

Institute for Research in Biomedicine

UNKNOWN

lead

Ricardo Pereira Mestre

OTHER